These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34571066)

  • 1. Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients.
    Nacasch N; Erez D; Lishner M; Benchetrit S; Rozenberg I; Sarel E; Shitrit P; Wand O; Cohen-Hagai K
    Am J Kidney Dis; 2022 Jan; 79(1):137-139. PubMed ID: 34571066
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients.
    Attias P; Sakhi H; Rieu P; Soorkia A; Assayag D; Bouhroum S; Nizard P; El Karoui K
    Kidney Int; 2021 Jun; 99(6):1490-1492. PubMed ID: 33887317
    [No Abstract]   [Full Text] [Related]  

  • 3. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
    Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
    Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
    Grupper A; Sharon N; Finn T; Cohen R; Israel M; Agbaria A; Rechavi Y; Schwartz IF; Schwartz D; Lellouch Y; Shashar M
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1037-1042. PubMed ID: 33824157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antibody response to two different mRNA Covid-19 vaccines in patients on hemodialysis.
    Ionita C; Marcelli D; Nita C; Anton C; Berca S; Vacar S; Schiller O; Gheorghiu C; Barth C
    J Nephrol; 2022 Jan; 35(1):143-151. PubMed ID: 34978050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients-A prospective observational study.
    Al-Muhaiteeb A; AlSahow A; Al-Yousef A; AlHelal B; Alrajab H; Bahbahani Y; Dewidar N; Fanous GNM
    Hemodial Int; 2022 Apr; 26(2):216-222. PubMed ID: 34989097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody response in BNT162b2 mRNA-vaccinated dialysis patients and those with coronavirus disease 2019: Long-term follow-up.
    Berar Yanay N; Freimann S; Shapira M; Gershkovich R; Peleg N; Mtanis L; Armaly Z
    Hemodial Int; 2022 Apr; 26(2):281-283. PubMed ID: 34939309
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study.
    Mirioglu S; Kazancioglu R; Cebeci E; Eren N; Sakaci T; Alagoz S; Tugcu M; Tuglular S; Sumbul B; Seyahi N; Ozturk S
    Nephron; 2023; 147(7):392-400. PubMed ID: 36603567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral Response to the Third Dose of BNT162b2 COVID-19 Vaccine among Hemodialysis Patients.
    Agur T; Zingerman B; Ben-Dor N; Alkeesh W; Steinmetz T; Rachamimov R; Korzets A; Rozen-Zvi B; Herman-Edelstein M
    Nephron; 2023; 147(3-4):185-192. PubMed ID: 35896080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dialysis modality, humoral response to vaccine, and SARS-CoV-2 infection risk: Comparative prospective evaluation.
    Bnaya A; Nacasch N; Einbinder Y; Shavit L; Erez D; Shashar M; Grupper A; Benchetrit S; Wand O; Cohen-Hagai K
    Semin Dial; 2023; 36(5):382-389. PubMed ID: 37042666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis.
    Yau K; Chan CT; Abe KT; Jiang Y; Atiquzzaman M; Mullin SI; Shadowitz E; Liu L; Kostadinovic E; Sukovic T; Gonzalez A; McGrath-Chong ME; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Levin A; Blake PG; Colwill K; Gingras AC; Hladunewich MA
    CMAJ; 2022 Feb; 194(8):E297-E305. PubMed ID: 35115375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+ B Lymphocytes and the Naïve CD45RA to Memory CD45RO CD4+ T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients.
    Duni A; Markopoulos GS; Mallioras I; Pappas H; Pappas E; Koutlas V; Tzalavra E; Baxevanos G; Priska S; Gartzonika K; Mitsis M; Dounousi E
    Front Immunol; 2021; 12():760249. PubMed ID: 34925330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients.
    Housset P; Kubab S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Caudwell V; Faucon AL
    J Nephrol; 2022 Apr; 35(3):783-785. PubMed ID: 35192157
    [No Abstract]   [Full Text] [Related]  

  • 17. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Is Associated with Medical Conditions.
    Guinault D; Bernier M; Delarche A; Neuville S; Milioto O; Molinari N; Dahan P
    Nephron; 2022; 146(6):553-558. PubMed ID: 35477156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response to BNT162b2 mRNA vaccine in healthcare workers and residents in a long-term care facility.
    Kitagawa T; Kuramitsu Y; Nakagawa K; Ohta T; Akino K; Asaka M; Kobayashi M
    Geriatr Gerontol Int; 2022 Feb; 22(2):179-181. PubMed ID: 35014140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.